Cargando…

Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study

Few proton magnetic resonance spectroscopy studies have explored chemotherapy-related biochemical changes in brain regions. This observational study aimed to longitudinally assess short-term cognitive changes and brain metabolite concentrations in women undergoing chemotherapy for breast cancer. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Beyer, Joana, Couch, Ronan, Ruddy, Kathryn J., Zeydan, Burcu, Tosakulwong, Nirubol, Lesnick, Timothy G., Novotny, Paul J., Kohli, Sadhna, Cerhan, Jane H., Pruthi, Sandhya, Kantarci, Kejal, Kara, Firat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589550/
https://www.ncbi.nlm.nih.gov/pubmed/37861526
http://dx.doi.org/10.1097/MD.0000000000035524
_version_ 1785123815652589568
author Beyer, Joana
Couch, Ronan
Ruddy, Kathryn J.
Zeydan, Burcu
Tosakulwong, Nirubol
Lesnick, Timothy G.
Novotny, Paul J.
Kohli, Sadhna
Cerhan, Jane H.
Pruthi, Sandhya
Kantarci, Kejal
Kara, Firat
author_facet Beyer, Joana
Couch, Ronan
Ruddy, Kathryn J.
Zeydan, Burcu
Tosakulwong, Nirubol
Lesnick, Timothy G.
Novotny, Paul J.
Kohli, Sadhna
Cerhan, Jane H.
Pruthi, Sandhya
Kantarci, Kejal
Kara, Firat
author_sort Beyer, Joana
collection PubMed
description Few proton magnetic resonance spectroscopy studies have explored chemotherapy-related biochemical changes in brain regions. This observational study aimed to longitudinally assess short-term cognitive changes and brain metabolite concentrations in women undergoing chemotherapy for breast cancer. We analyzed 11 women with newly diagnosed stage 1 to 3 breast cancer. Patients were evaluated via objective cognitive testing, and patient self-report tests. Patients were examined using single voxel proton magnetic resonance spectroscopy in the medial frontal cortex, posterior cingulate gyrus, and left thalamus at baseline and after the completion of chemotherapy on a 1.5 Tesla scanner. At the posttreatment evaluation as compared to baseline, 7 of the 10 (70%) patients reported worsening memory on the MD Anderson symptom inventory (annualized change = 1.82 ± 2.88, P = .08), while the delayed recall raw score of the Rey Osterrieth complex figure test did not change from pre- to post-chemotherapy (mean annualized change = 5.00 ± 14.38, P = .30). The annualized change in the creatine concentration in the posterior cingulate gyrus was statistically significant. The annualized change in the MD Anderson symptom inventory was negatively correlated with the annualized change in the medial frontal N-acetylaspartate (Spearman correlation coefficient [rho] = −0.78, P = .01) and positively correlated with the annualized change in the posterior cingulate gyrus creatine (rho = 0.66, P = .04). Annualized changes in the Rey Osterrieth complex figure test were positively correlated with annualized changes in choline (rho = 0.83, P = .01) in the medial frontal cortex, choline (rho = 0.76, P = .04) in the left thalamus, and creatine (rho = 0.73, P = .02) in the medial frontal cortex. Our data suggest that chemotherapy may lead to the worsening of self-reported memory function, which is associated with alterations in brain metabolites.
format Online
Article
Text
id pubmed-10589550
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105895502023-10-22 Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study Beyer, Joana Couch, Ronan Ruddy, Kathryn J. Zeydan, Burcu Tosakulwong, Nirubol Lesnick, Timothy G. Novotny, Paul J. Kohli, Sadhna Cerhan, Jane H. Pruthi, Sandhya Kantarci, Kejal Kara, Firat Medicine (Baltimore) 7400 Few proton magnetic resonance spectroscopy studies have explored chemotherapy-related biochemical changes in brain regions. This observational study aimed to longitudinally assess short-term cognitive changes and brain metabolite concentrations in women undergoing chemotherapy for breast cancer. We analyzed 11 women with newly diagnosed stage 1 to 3 breast cancer. Patients were evaluated via objective cognitive testing, and patient self-report tests. Patients were examined using single voxel proton magnetic resonance spectroscopy in the medial frontal cortex, posterior cingulate gyrus, and left thalamus at baseline and after the completion of chemotherapy on a 1.5 Tesla scanner. At the posttreatment evaluation as compared to baseline, 7 of the 10 (70%) patients reported worsening memory on the MD Anderson symptom inventory (annualized change = 1.82 ± 2.88, P = .08), while the delayed recall raw score of the Rey Osterrieth complex figure test did not change from pre- to post-chemotherapy (mean annualized change = 5.00 ± 14.38, P = .30). The annualized change in the creatine concentration in the posterior cingulate gyrus was statistically significant. The annualized change in the MD Anderson symptom inventory was negatively correlated with the annualized change in the medial frontal N-acetylaspartate (Spearman correlation coefficient [rho] = −0.78, P = .01) and positively correlated with the annualized change in the posterior cingulate gyrus creatine (rho = 0.66, P = .04). Annualized changes in the Rey Osterrieth complex figure test were positively correlated with annualized changes in choline (rho = 0.83, P = .01) in the medial frontal cortex, choline (rho = 0.76, P = .04) in the left thalamus, and creatine (rho = 0.73, P = .02) in the medial frontal cortex. Our data suggest that chemotherapy may lead to the worsening of self-reported memory function, which is associated with alterations in brain metabolites. Lippincott Williams & Wilkins 2023-10-20 /pmc/articles/PMC10589550/ /pubmed/37861526 http://dx.doi.org/10.1097/MD.0000000000035524 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 7400
Beyer, Joana
Couch, Ronan
Ruddy, Kathryn J.
Zeydan, Burcu
Tosakulwong, Nirubol
Lesnick, Timothy G.
Novotny, Paul J.
Kohli, Sadhna
Cerhan, Jane H.
Pruthi, Sandhya
Kantarci, Kejal
Kara, Firat
Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study
title Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study
title_full Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study
title_fullStr Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study
title_full_unstemmed Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study
title_short Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study
title_sort longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: observational study
topic 7400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589550/
https://www.ncbi.nlm.nih.gov/pubmed/37861526
http://dx.doi.org/10.1097/MD.0000000000035524
work_keys_str_mv AT beyerjoana longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT couchronan longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT ruddykathrynj longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT zeydanburcu longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT tosakulwongnirubol longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT lesnicktimothyg longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT novotnypaulj longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT kohlisadhna longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT cerhanjaneh longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT pruthisandhya longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT kantarcikejal longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy
AT karafirat longitudinalcognitivefunctionandbrainmetabolitesinwomenreceivingchemotherapyforstage1to3breastcancerobservationalstudy